Guokai Jintai Invests in Baoxin Asia-Pacific Biotech, Acquiring 10% Stake to Advance Regenerative Medicine R&D
Recently, Baoxin Asia-Pacific Biotechnology (Shenzhen) Co., Ltd. (hereinafter referred to as “Baoxin Asia-Pacific”) has celebrated a series of auspicious developments. The company not only secured investment from CDB Jintai Capital Investment Co., Ltd. (hereinafter referred to as “CDB Jintai”), but also became the first enterprise to settle in the “International Biopharmaceutical Industrial Park” in Shenzhen.
Following its capital injection into Baoxin Asia-Pacific, CDB Jintai acquired approximately a 10% equity stake in the company.“We are delighted that heavyweight investors have recognized the growth prospects of Baoxin Asia-Pacific,” said Wei Xin, CEO of Baoxin Asia-Pacific. “The capital raised will be used to strengthen support for our ongoing clinical development, enabling us to obtain clinical data more rapidly. It will also support the establishment of an international regenerative medicine R&D center to develop more innovative biotechnologies, thereby meeting people’s aspirations for a better and healthier life.”“We anticipate that two to three stem cell-based therapeutics for chronic diseases will enter clinical trials in 2020, while we will also further invest in the development of personalized product lines in regenerative aesthetic medicine.”
Baoxin Asia-Pacific Biotechnology (Shenzhen) Co., Ltd. was established on January 4, 2016, as a joint venture between Hong Kong’s Chuangjian Group and American CryoStem, a company listed on the NASDAQ in the United States. As a high-tech biotechnology enterprise, it leverages American CryoStem’s patented technology for viable cell tissue cryopreservation. This technology enables the freezing of autologous adipose tissue while preserving cell viability, ensuring its future applicability in various fields such as fat grafting, thereby realizing the concept of “one-time liposuction, lifelong benefits.”This technology advances from traditional cell cryopreservation to tissue cryopreservation, enabling the intact preservation of adipose tissue and achieving a viability rate of up to 97.6%. It has received approval from the U.S. FDA and is registered with China’s CFDA.
Currently, we primarily serve the vast medical aesthetics market in mainland China. By introducing advanced and viable biotechnologies and medical technologies from around the world—including adipocyte storage technology, stem cell banking, and genetic testing services—we enable ordinary citizens to keep pace with rapidly evolving international medical technologies and access professional, cutting-edge, and reliable health management services.
According to Wei Xin, their R&D strategy encompasses stem cell therapeutic products independently developed in their Chinese laboratories, as well as biotechnologies licensed from partners that show potential efficacy for cosmetic and plastic surgery procedures and chronic age-related diseases prevalent in China and the Asia-Pacific region. To enhance their R&D capabilities, Baoxin Asia-Pacific is establishing a robust, integrated R&D platform in China—spanning from laboratory research to clinical trials—to meet the extensive demand in the regenerative medical aesthetics and regenerative medicine markets across China and throughout Asia.
Many people desire to maintain a youthful appearance. However, as age advances, hormonal changes within the body lead to visible signs of skin aging, such as fine lines, wrinkles, and volume loss. The primary causes are the depletion of subcutaneous collagen and fat, along with the descent of fat pads. It is difficult to replenish lost fat in specific areas through oral supplementation. Currently, the most common methods for smoothing the skin involve injections of botulinum toxin or hyaluronic acid; however, these offer short-lasting results and are not suitable for long-term use.
Baoxin Asia-Pacific has exclusively introduced the patented ATGRAFT™ technology from the U.S.-listed company American CryoStem. This technology enables the storage of customized quantities of adipose cells, tailored to specific body areas and professional requirements, for future use in improving wrinkles and hand lines, as well as enhancing breast contour. Adipose tissue is preserved with ultra-high viability for over 20 years, making small-volume, repeated, multi-session, and precision fat grafting a reality. The advent of this cutting-edge biotechnology in full-fat preservation is not only a miracle of innovative science but also a revolutionary breakthrough in the field of regenerative medicine.
Meanwhile, Baoxin Asia-Pacific is building a massive biobank of tissue and cell samples, securing non-renewable raw materials for future biopharmaceutical development. This project fills a gap in China’s cryomedicine sector and provides robust support for maintaining health and restoring beauty.
In response to the national call and to accelerate the realization of the “Healthy China” vision proposed by President Xi Jinping, under the guidance of the Outline of the Healthy China 2030 Plan, the Shenzhen Municipal Committee of the Communist Party of China and the Shenzhen Municipal People’s Government have begun to focus on the future biotechnology and regenerative medicine industry. Particularly against the backdrop of sustained economic development, the potential of the biotechnology and regenerative medicine sector will be further unleashed.
As the core of a national-level biotechnology industry base, the park features 220,000 square meters of industrial space in its Phase I development. It continuously attracts upstream and downstream enterprises in the biopharmaceutical sector, adopting a business model that integrates park development, operational services, and industrial investment to establish a comprehensive health ecosystem covering incubation, acceleration, and production. Currently, the occupancy rate of medical device facilities in Phase I exceeds 83%, with the park’s total annual output value reaching RMB 1.628 billion last year.
As one of the first enterprises to settle in the “International Biopharmaceutical Industrial Park,” Baoxin Asia-Pacific will receive government support in various areas, including industrial and talent policies. Meanwhile, this will further promote and influence the clustering of upstream and downstream companies in the life and health industry within the Futian International Biopharmaceutical Industrial Park, serving as a key platform for cultivating industrial clusters.
The signing of the agreement between the two parties will provide a significant boost to the development of biotechnology and regenerative medicine in China. The advancement and growth of biomedical and regenerative medicine rely not only on progress in medical technology and biotechnology but also on government support. By leveraging industrial parks to aggregate abundant technological innovation and intellectual resources, we can jointly fulfill the important mission of driving innovation and promoting scientific development.
Such national-level development zones (including National High-Tech Industrial Development Zones and National Economic and Technological Development Zones) are being established across China, with the number of parks increasing from 219 in 2011 to 364 in 2015, representing a compound annual growth rate (CAGR) of 13.5%.
After a period of rapid growth between 2012 and 2013, the number of national-level development zones entered a phase of steady expansion. Against the backdrop of the “Four Comprehensives” strategic layout, the approval process for such zones became more prudent. In 2014, only nine new national-level development zones were approved, representing a growth rate of just 2.8%.In 2015, the number of newly approved national-level development zones reached 31, representing a growth rate of 9.3%. By the end of 2015, there were a total of 145 national-level high-tech industrial development zones and 219 national-level economic and technological development zones.
In addition to establishing its presence in the industrial park, Baoxin Asia-Pacific has also introduced the ATGRAFT (Quan Zhi Ran) project. This technology is based on a U.S. patent (Patent Nos.: PCT/US2013/044621; WO2013184978A2), has been marketed in the United States and Japan, and has been widely applied for over five years.
Whole-fat preservation technology enables the cryopreservation of human adipose tissue under sterile conditions with high cell viability, allowing for the long-term storage of autologous fat for applications in aesthetic plastic surgery and autologous tissue repair. This approach significantly reduces the trauma and pain associated with repeated liposuction procedures, offering a novel and exciting option for both patients and physicians.
The advent of whole-fat preservation technology has turned the ideal of long-term cryopreservation of adipose tissue with excellent biological activity into reality. It not only meets the demands of aesthetic and reconstructive applications over the coming decades but also enables facial and systemic anti-aging treatments, while simultaneously advancing the field of human regenerative medicine.
Over the past five years, the compound annual growth rate (CAGR) of China’s medical aesthetics industry has remained above 30%. China boasts a large consumer base for medical aesthetic services, driven by favorable factors such as shifting consumer perceptions, rising disposable income per capita, and low market penetration. As a sunrise industry, the medical aesthetics sector has received strong support from the Shenzhen Municipal Government, attracting multi-party capital investment as well as increased spending on technology introduction and research and development.
Over the next decade, China’s medical aesthetics industry will maintain significant room for growth. Regenerative medicine holds broad prospects for application in the field of medical aesthetics. Baoxin Asia-Pacific will experience even more rapid development, thereby promoting the Shenzhen Municipal Government and the medical aesthetics and general health industry to jointly build a new ecosystem for the medical aesthetics sector.